Investigational drug · Phase 2
YKST02
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Multiple Myeloma (RRMM).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "YKST02"
First trial start
2027
Dec 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YKST02", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Multiple Myeloma (RRMM)
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "YKST02" as an intervention, largest first.
Excyte Biopharma LtdIndustry
NCT06574568 · 70 participants (planned) · Start Jun 14, 2024 · Primary completion Dec 31, 2026
Drug: YKST02 · For: Relapsed or Refractory Multiple Myeloma
Sites: Beijing, China; Foshan, China; Guangzhou, China · 12 sites in all
- Study of YKST02 in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruiting
Excyte Biopharma LtdIndustry
NCT07695740 · 64 participants (planned) · Start Dec 2027 · Primary completion Dec 2030
Drug: YKST02 · For: Relapsed or Refractory Multiple Myeloma (RRMM)
Sites: Beijing, China
- Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus ErythematosusNot yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07512947 · 30 participants (planned) · Start May 2026 · Primary completion Mar 30, 2028
Drug: YKST02; YK012 · For: System Lupus Erythematosus(SLE)
Sites: Wuhan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07498673 · 12 participants (planned) · Start May 6, 2026 · Primary completion Mar 30, 2027
Drug: YKST02 · For: Primary IgA Nephropathy
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed or Refractory Multiple Myeloma (RRMM)
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
- Purinostat MesylatePhase 32 trials
Chengdu Zenitar Biomedical Technology Co., Ltd · Relapsed or Refractory Multiple Myeloma (RRMM), Recurrent and Refractory Diffuse Large B-cell Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.